Kellogg Researchers Develop New Nanoparticle with Potential to Treat Ocular Cancer
News Mar 01, 2016
Researchers at the University of Michigan Kellogg Eye Center have developed a new nanoparticle that uses a tumor cell’s protective mechanism against itself — short-circuiting tumor cell metabolism and killing tumor cells.“Our work uses a semiconducting nanoparticle with an attached platinum electrode to drive the synthesis of an anti-cancer compound when illuminated by light,” says Howard R. Petty, Ph.D., Professor of Ophthalmology and Visual Sciences and of Microbiology and Immunology.
“The nanoparticle mimics the behavior of NADPH oxidase, an enzyme used by immune cells to kill tumor cells and infectious agents. Since tumor cells typically use NADPH to protect themselves from toxins, the more NADPH they synthesize for protection, the faster they die.” disruption of the tumor cell due to treatment with nanoparticles and visible light. This image shows the disruption of the tumor cell due to treatment with nanoparticles and visible light.
In a four-year study conducted on the mouse model in advanced breast cancer metastasis in the eye’s anterior chamber, Dr. Petty and colleagues found that the new nanoparticle not only killed tumor cells in the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kill. “Previous monotherapies have not extended the lifetimes of mice bearing this type of tumor,” says Dr. Petty. “Our work has shown that we can extend survival of the mice.”
The findings of the Kellogg team are detailed in a new paper titled WO3/Pt nanoparticles are NADPH oxidase biomimetics that mimic effector cells in vitro and in vivo published in Nanotechnology on February 19, 2016. Joining Dr. Petty as co-authors of the paper are research associate Andrea J. Clark, and undergraduates Emma L. Coury and Alexandra M. Meilhac.
“This treatment offers many advantages,” says Dr. Petty. “The nanoparticle produces about 20 million toxins per hour in each cell. Also, the nanoparticle is activated by light, so it can be turned on and off simply by exposing it to the correct color of visible light.” This nanotechnology also has the potential to be used for multiple applications in ophthalmology and other disciplines.
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE